HC Wainwright Expects Lower Earnings for ArriVent BioPharma

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Stock analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of ArriVent BioPharma in a report issued on Tuesday, November 11th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($4.32) per share for the year, down from their previous estimate of ($4.30). HC Wainwright currently has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2025 earnings at ($0.84) EPS, Q1 2026 earnings at ($0.87) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.65) EPS.

Other analysts also recently issued reports about the stock. Citigroup reduced their price target on shares of ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday. Zacks Research lowered shares of ArriVent BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. B. Riley upgraded shares of ArriVent BioPharma to a “strong-buy” rating in a research note on Monday, August 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, ArriVent BioPharma currently has an average rating of “Moderate Buy” and an average target price of $38.86.

ArriVent BioPharma Stock Down 2.7%

Shares of AVBP traded down $0.54 during midday trading on Thursday, reaching $19.66. 28,811 shares of the stock were exchanged, compared to its average volume of 276,578. The company has a market cap of $811.56 million, a price-to-earnings ratio of -4.64 and a beta of 1.11. The firm has a 50 day simple moving average of $19.07 and a 200-day simple moving average of $20.27. ArriVent BioPharma has a 12-month low of $15.47 and a 12-month high of $32.01.

ArriVent BioPharma (NASDAQ:AVBP) last released its earnings results on Monday, November 10th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.05).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its position in shares of ArriVent BioPharma by 9,747.6% during the third quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after acquiring an additional 2,047 shares in the last quarter. Barclays PLC grew its position in ArriVent BioPharma by 10.9% in the third quarter. Barclays PLC now owns 129,935 shares of the company’s stock valued at $2,397,000 after purchasing an additional 12,723 shares in the last quarter. Corient IA LLC acquired a new stake in ArriVent BioPharma in the 3rd quarter valued at $618,000. Dimensional Fund Advisors LP bought a new stake in ArriVent BioPharma during the 3rd quarter worth about $261,000. Finally, Rafferty Asset Management LLC boosted its stake in shares of ArriVent BioPharma by 118.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 34,361 shares of the company’s stock worth $634,000 after buying an additional 18,612 shares during the last quarter. 9.48% of the stock is currently owned by institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.